by GlobeNewsWire | Jul 18, 2016 | Globe Newswire
PRINCETON, N.J., July 18, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), has been classified...
by GlobeNewsWire | Jul 6, 2016 | Globe Newswire
Enrollment to commence this summer PRINCETON, N.J., July 06, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it reached an agreement with the U.S. Food and Drug...
by GlobeNewsWire | Jun 27, 2016 | Globe Newswire
PRINCETON, N.J., June 27, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that their annual Investor & Analyst Day, scheduled for Tuesday, June 28, 2016 at 1:30...
by GlobeNewsWire | Jun 8, 2016 | Globe Newswire
FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer PRINCETON, N.J., June 08, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced...
by GlobeNewsWire | Jun 6, 2016 | Globe Newswire
Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumabPRINCETON, N.J., June 06, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical...